QC
WHWK

Quadrature Capital’s Whitehawk Therapeutics WHWK Stock Holding History

Quadrature Capital’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,447
Closed -$27.7K – 1976
2025
Q4 		$27.7K Buy
+11,447
New +$26.3K ﹤0.01% 1199

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Quadrature Capital's WHWK Position: Q1 2026 in Review

Quadrature Capital sold out of Whitehawk Therapeutics (WHWK) in Q1 2026, closing a stake of 11,447 shares — an estimated $27.7K sold.

Quadrature Capital first reported a position in WHWK in Q4 2025 and held it in 1 quarter. The position peaked at $27.7K in Q4 2025. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Quadrature Capital reported no remaining Whitehawk Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quadrature Capital sold 11,447 Whitehawk Therapeutics shares in Q1 2026, an estimated $27.7K.
  • Quadrature Capital first reported a position in Whitehawk Therapeutics in Q4 2025 and held it in 1 quarter.
  • Quadrature Capital's Whitehawk Therapeutics position peaked at $27.7K in Q4 2025.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Quadrature Capital's 13F filing for Q1 2026, filed 15 May 2026.